Abstract Details

Title Extended Follow Up Data on the Efficacy and Safety of Cladribine for Multiple Sclerosis in a Greater London Hospital

Topic Multiple Sclerosis

Presentation(s) P12 - Poster Session 12 (11:45 AM-12:45 PM)

Poster/Presentation
Number 1-009

Objective To assess the efficacy and safety of cladribine use in patients with active relapsing remitting multiple sclerosis over an extended follow up period in a British cohort.

Background

Oral cladribine has been proven effective in clinical trials of active relapsing-remitting multiple sclerosis (aRRMS). Few studies report real world data. This study assessed efficacy and safety of oral cladribine with an average follow-up of 41.6 months in a large neuroscience centre in London, UK.

Design/Methods

Data were retrospectively collected on relapses, new MRI lesions, EDSS change, annualised relapse rates (ARR), lymphocyte counts, and infections.

Results

83 patients were included in our study: 71 had cladribine years 1+2; 12 had only year 1; median follow-up 41.6 months. Of 83 patients, 7 (8.4%) had a relapse, 18 (21.7%) developed new MRI lesions, 16 (19.3%) had EDSS progression, and 16 (19.3%) had EDSS improvement. NEDA-3 was seen in 54/83 (65.1%). PIRA (progression independent of relapse activity) was seen in 13/83 (15.7%) and PIA (progression independent of any inflammatory activity) in 8/83 (9.6%). Lymphopenia was seen in 65.1% patients (grade 3 = 12/83; grade 4 = 0).

Conclusions

The number of patients who had relapses, and rates of NEDA-3, PIRA and PIA were similar to other reported studies with similar or shorter follow-up. Our data confirms that cladribine is an effective treatment for aRRMS.

Authors/Disclosures
Miriam Mattoscio, MD, PhD, FAAN (Barking Havering and Redbridge University Hospitals Trust) PRESENTER	Dr. Mattoscio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK SERONO. Dr. Mattoscio has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MERCK SERONO.
Moneeb Nasir, MBBS	Dr. Nasir has nothing to disclose.
Kasun U. Athukoralage, MD, MBBS (National Hospital of Sri Lanka)	Dr. No has nothing to disclose.
Plaxedes Rabvukwa, RN	Miss Rabvukwa has nothing to disclose.
Sarah E. Fuller, RN	Mrs. Fuller has nothing to disclose.
Laura Azzopardi, MD, PhD	Dr. Azzopardi has nothing to disclose.
Abhijit Chaudhuri, MD, PhD	Dr. Chaudhuri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Chaudhuri has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BMJ.

��ɫ��

��ɫ��